Key facts
- This page summarizes Flagship Ventures Fund V General Partner LLC's Form 4 filing for Sigilon Therapeutics, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Aug 2023, 16:15.
Flagship Ventures Fund V General Partner LLC - 11 Aug 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 11 Aug 2023
- Net transaction value
- -$11,901,982
- SEC form
- 4
- Accepted by SEC
- 15 Aug 2023, 16:15:09 UTC
- Prior SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- Flagship Ventures Fund V General Partner LLC, By: /s/ Noubar B. Afeyan Ph.D., Title: Manager
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Flagship Ventures Fund V General Partner LLC filed Form 4 for Sigilon Therapeutics, Inc. on 15 Aug 2023.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: -$11,901,982.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGTX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- $10,201,699
- Shares
- -683,760
- Change %
- -100%
- Price
- $14.92*
- Shares after
- 0
- Date
- 11 Aug 2023
- Ownership
- By Flagship Ventures Fund V, L.P.
- Footnotes
- F1, F2, F3
SGTX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- $1,700,283
- Shares
- -113,960
- Change %
- -100%
- Price
- $14.92*
- Shares after
- 0
- Date
- 11 Aug 2023
- Ownership
- By Flagship Pioneering Special Opportunities Fund II, L.P.
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Flagship Ventures Fund V General Partner LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones.
Footnote F2
Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split.
Footnote F3
Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F4
Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.